This Key Event Relationship is licensed under the Creative Commons BY-SA license. This license allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
Relationship: 1069
Title
N/A, Neurodegeneration leads to Impairment, Learning and memory
Upstream event
Downstream event
AOPs Referencing Relationship
| AOP Name | Adjacency | Weight of Evidence | Quantitative Understanding | Point of Contact | Author Status | OECD Status |
|---|---|---|---|---|---|---|
| Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development leads to neurodegeneration with impairment in learning and memory in aging | adjacent | High | Arthur Author (send email) | Open for citation & comment | WPHA/WNT Endorsed | |
| Activation of MEK-ERK1/2 leads to deficits in learning and cognition via ROS and apoptosis | adjacent | Not Specified | Not Specified | Cataia Ives (send email) | Under development: Not open for comment. Do not cite |
Taxonomic Applicability
Sex Applicability
| Sex | Evidence |
|---|---|
| Unspecific | Moderate |
Life Stage Applicability
| Term | Evidence |
|---|---|
| Old Age | Moderate |
Animal models of neurodegenerative diseases, in particular Alzheimer's disease, contributed to the elucidation of the link between amyloid protein and tau hyperphosphorylation and cognitive deficits. Bilateral injections of amyloid-b peptide in the frontal cortex of rats leads to progressive decline in memory and neurodegeneration in hippocampus (for review see Eslamizade et al., 2016). Recent findings have shown that soluble forms of Ab rather than insoluble forms (fibrils and plaques) are associated with memory impairment in early stages of Alzheimer's disease (for review see Salgado-Puga and Pena-Ortega, 2015). Several lines of evidence suggest that the small oligomeric forms of Ab and tau may act synergistically to promote synaptic dysfunction in Alzheimer's disease (for review see Guerrerro-Minoz et al., 2015). Some reports proposed the concept of imbalance between production and clearance of Ab42 and related Ab peptides, as an initiating factor inducing hyperphosphorylation of tau and leading to neuritic dystrophy and synaptic dysfunction (for review see Selkoe and Hardy, 2016). Recent trials of three different antibodies against amyloid peptides have suggested a slowing of cognitive decline in post hoc analyses of mild Alzheimer subjects (for review see Selkoe and Hardy, 2016). Therefore cognitive deficits may be related to the level and extent of classical Alzheimer pathology landmarks, but it is also influenced by neurodegeneration (for review see Braskie and Thompson, 2013). Indeed decreased hippocampal volume due to widespread neurodegeneration and visualized by neuroimaging appears to be a significant predictor of memory decline (for review see Braskie and Thompson, 2016).
This KER was developed, in part, as part of an Environmental Protection Agency effort to represent putative AOPs from peer-reviewed literature which were heretofore unrepresented in the AOP-Wiki. The KER is referenced in publications which were cited in the originating work for the putative AOP "Activation of MEK-ERK1/2 leads to deficits in learning and cognition via ROS and apoptosis", Katherine von Stackelberg & Elizabeth Guzy & Tian Chu & Birgit Claus Henn, 2015. Exposure to Mixtures of Metals and Neurodevelopmental Outcomes: A Multidisciplinary Review Using an Adverse Outcome Pathway Framework, Risk Analysis, John Wiley & Sons, vol. 35(6), pages 971-1016, June.
In July 2023 updates were made to the then empty Taxonomic, Sex, and Life Stage Applicability fields and in the Empirical Evidence field with the addition of Wozniak et al., (2004), Allison et al., (2021), and Huang et al., (2012) studies.
| ID | Experimental Design | Species | Upstream Observation | Downstream Observation | Citation (first author, year) | Notes |
|---|
| Title | First Author | Biological Plausibility |
Dose Concordance |
Temporal Concordance |
Incidence Concordance |
|---|
Biological Plausibility
Dose Concordance Evidence
Temporal Concordance Evidence
Incidence Concordance Evidence
Uncertainties and Inconsistencies
There are some inconsistencies regarding the time of exposure. Some papers clearly show that early Pb exposure increases amyloid and tau pathology and cognitive decline in aging. But few studies have addressed this complex question by using an ad hoc experimental design. Other studies have descibed the effects of lifetime or long-term exposure on cognitive functions but without a precise desciption of exposure onset and duration.
Is it known how much change in the first event is needed to impact the second? Are there known modulators of the response-response relationships? Are there models or extrapolation approaches that help describe those relationships?
|
Endpoints relevant for KEup Neurodegeneration in hippocampus and cortex |
Endpoints relevant for KEdown Impairment of learning and memory |
Model and treatments |
Reference |
|
|
|
|
|
|
0.5 -1x increase in amyloid peptides accumulation if early postnatal exposure |
Decrease in cognitive functions (Morris water maze, Y maze testing for spatial memory and memory, a hippocampus -dependent task)
|
Mice exposed to Pb 0.2% in drinking water from PND 1 to 20
or from PND 1-20 and from 7-9 months of age
|
Bihaqui et al., 2014
|
|
About 5x increase of neuronal death in hippocampus
Return to control levels in vivo and in vitro after minocycline treatment
|
Long Term Potentiation (LTP) was lost in Pb-treated rats and restores upon minocycline treatment
|
Rats exposed to Pb (100 ppm) from 24 to 80 days of age
|
Liu et al., 2012 |
|
About 2x more Abeta1-40 and of Abeta1-42 in CSF, cortex and hippocampus and 2x more amyloid plaque load than control
Pb co-localized with amyloid plaques. |
Impaired spatial learning ability (Morris maze) |
Human Tg-SWDI APP mice received by oral gavage 50mg/kg Pb once daily for 6 weeks.
Pb level in brain 60 microg/dL (similar level than those found in children, Gu et al., 2011)
|
Gu et al., 2012 |
</div>